Salt Lake City, UT (PRWEB) October 31, 2013
Tute Genomics made their public debut last week at the 2013 American Society for Human Genetics (ASHG) conference in Boston, MA. Tute, founded in 2012, is a cloud-based, professional grade clinical genome interpretation engine that has the ability to analyze and annotate entire human genomes in a rapid and cost-effective way, faster than any other platform. Tute Genomics helps researchers and laboratories identify and prioritize disease variants to aid in the genetic diagnosis of human diseases and target treatments based on an individual’s ability to respond to therapies.
Tute was co-founded by Kai Wang, PhD of the University of Southern California and Reid Robison, MD MBA of the University of Utah and Utah Foundation for Biomedical Research. Dr. Wang is a renowned computational biologist and creator of ANNOVAR, one of the most widely used tools for whole genome analysis. Dr. Robison is a physician and geneticist, turned data scientist, and co-founder of Anolinx, a healthcare data analytics firm that was acquired in 2012.
Tute’s technology was developed upon the basis of Dr. Wang’s expertise in human genome annotation and disease gene finding. Recognizing the need for an application that can streamline the analysis process, Tute created a secure, cloud-based pipeline inclusive of over 60 different annotations to provide a thorough and rapid analysis of whole genomes and exomes, resulting in substantial time savings, and more thorough and accurate information for anyone who interacts with genomic data. The goal: interpret data faster for clinically relevant findings in an effort to make “precision medicine” a reality.
The timing of Tute’s launch couldn’t be better. The cost of genome sequencing is dropping rapidly and we are in the middle of a genomics revolution that is poised to transform medicine. Tute Genomics is opening a new door for personalized medicine with cloud-based software that allows researchers & healthcare organizations to analyze entire human genomes for health and biomedical discovery. There is an urgent need for tools to analyze the massive influx of “big genomic data” that is resulting from increased use of next-generation sequencing in healthcare and in research labs not only nationwide, but around the globe.
About Tute Genomics:
Tute Genomics is a web-based clinical genome interpretation engine that is robust, professional grade, lives in the cloud, and has the ability to analyze and annotate personal genomes in a rapid and cost-effective way. Whole genome sequencing is transforming research & medicine. Researchers and laboratories are getting flooded with high-throughput genetics data sets, but the ability to infer biological insights and guide decision making lag behind significantly. There is an urgent need for tools to analyze genetic variants from personal genomes in research and in clinical settings. Tute Genomics is solving this problem with a web-based clinical genome interpretation engine. To learn more about Tute Genomics, please visit http://www.tutegenomics.com.
About Kai Wang:
Dr. Kai Wang is President and co-founder of Tute Genomics. Dr. Wang is currently an Assistant Professor of Psychiatry and Preventive Medicine at the Zilkha Neurogenetic Institute, University of Southern California. He was trained as a molecular biologist at Peking University in China, and later became interested in Computational Biology and obtained a Ph.D. at the University of Washington. He completed postdoctoral training at the University of Pennsylvania and Children’s Hospital of Philadelphia, working on genomic analysis of human diseases. His current research focuses on next-generation sequencing data analysis, including the development of functional interpretation approaches, CNV calling methods and pathway-based association tests. He is the creator of ANNOVAR, the most widely used genome annotation software, which has been downloaded over 30,000 times, and cited in over 400 scientific articles. Dr. Wang has over 100 scientific publications to date.
About Reid Robison:
Reid Robison, M.D., M.B.A. is CEO and co-founder of Tute Genomics. Dr. Robison is a board-certified psychiatrist, with fellowship training in both neurodevelopmental genetics and bioinformatics. After residency and fellowship training at the University of Utah, Dr. Robison joined as tenure track faculty where he co-directed a molecular genetics lab, studying the genetic basis of autism and other neurodevelopmental disorders, using next-generation sequencing technology. Dr. Robison has led over $10 million in pharmaceutical studies, and previously founded Clinical Methods, an innovative, data-driven Phase I-IV CNS trials site that was later acquired. Dr. Robison is also co-founder of Anolinx, a healthcare data analytics firm that was acquired in 2012.